Skip Nav Destination
Issues
1 November 2021
-
Cover Image
Cover Image
Blood cancer patients are among the most vulnerable to COVID-19 infection. In this issue, two clinical studies from Memorial Sloan Kettering Cancer Center show they may also be among the least protected by the vaccines. On page 568, Chung et al. report low antibody titers and even lower neutralizing activity among 551 patients with leukemia, lymphoma, and myeloma as compared to healthy controls. Venetoclax, kinase inhibitors, and B-cell antigen–targeting therapies further cripple vaccine-elicited immunity. On page 577, Tamari et al. show that immune recovery after cellular therapies of hematologic cancers correlates with response to COVID-19 vaccines. In a pooled data analysis of these and other studies, Ribas et al. (page 562) conclude that hematologic cancer patients have impaired antibody response to vaccination and boosters, and call for public health measures to protect this vulnerable group. Among the recommendations is to give booster vaccine doses to patient’s caregivers and household members. The cover image illustrates how this strategy can prevent viral spread to and from patients with blood cancer. Artwork by Katie Vicari.Close Modal - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 2643-3230
EISSN 2643-3249
In This Issue
In The Spotlight
Science in Society
Research Briefs
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies
David J. Chung; Gunjan L. Shah; Sean M. Devlin; Lakshmi V. Ramanathan; Sital Doddi; Melissa S. Pessin; Elizabeth Hoover; LeeAnn T. Marcello; Jennifer C. Young; Sawsan R. Boutemine; Edith Serrano; Saumya Sharan; Saddia Momotaj; Lauren Margetich; Christina D. Bravo; Genovefa A. Papanicolaou; Mini Kamboj; Anthony R. Mato; Lindsey E. Roeker; Malin Hultcrantz; Sham Mailankody; Alexander M. Lesokhin; Santosha A. Vardhana; David A. Knorr
Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy
Roni Tamari; Ioannis Politikos; David A. Knorr; Santosha A. Vardhana; Jennifer C. Young; LeeAnn T. Marcello; Sital Doddi; Sean M. Devlin; Lakshmi V. Ramanathan; Melissa S. Pessin; Erica Dunn; Meighan Palazzo; Christina D. Bravo; Genovefa A. Papanicolaou; Mini Kamboj; Miguel Angel Perales; David J. Chung; Gunjan L. Shah
Research Articles
Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
Maarten Fornerod; Jing Ma; Sanne Noort; Yu Liu; Michael P. Walsh; Lei Shi; Stephanie Nance; Yanling Liu; Yuanyuan Wang; Guangchun Song; Tamara Lamprecht; John Easton; Heather L. Mulder; Donald Yergeau; Jacquelyn Myers; Jennifer L. Kamens; Esther A. Obeng; Martina Pigazzi; Marie Jarosova; Charikleia Kelaidi; Sophia Polychronopoulou; Jatinder K. Lamba; Sharyn D. Baker; Jeffrey E. Rubnitz; Dirk Reinhardt; Marry M. van den Heuvel-Eibrink; Franco Locatelli; Henrik Hasle; Jeffery M. Klco; James R. Downing; Jinghui Zhang; Stanley Pounds; C. Michel Zwaan; Tanja A. Gruber; for the Berlin-Frankfurt-Munster Study Group (BFM)
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia
Akhilesh Kaushal; Ajay K. Nooka; Allison R. Carr; Katherine E. Pendleton; Benjamin G. Barwick; Julia Manalo; Samuel S. McCachren; Vikas A. Gupta; Nisha S. Joseph; Craig C. Hofmeister; Jonathan L. Kaufman; Leonard T. Heffner; Stephen M. Ansell; Lawrence H. Boise; Sagar Lonial; Kavita M. Dhodapkar; Madhav V. Dhodapkar
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Joshua F. Zeidner; Benjamin G. Vincent; Anastasia Ivanova; Dominic Moore; Karen P. McKinnon; Alec D. Wilkinson; Rupkatha Mukhopadhyay; Francesco Mazziotta; Hanna A. Knaus; Matthew C. Foster; Catherine C. Coombs; Katarzyna Jamieson; Hendrik Van Deventer; Jonathan A. Webster; Gabrielle T. Prince; Amy E. DeZern; B. Douglas Smith; Mark J. Levis; Nathan D. Montgomery; Leo Luznik; Jonathan S. Serody; Ivana Gojo
Overcoming Acquired Epigenetic Resistance to BTK Inhibitors
Arthur L. Shaffer, III; James D. Phelan; James Q. Wang; DaWei Huang; George W. Wright; Monica Kasbekar; Jaewoo Choi; Ryan M. Young; Daniel E. Webster; Yandan Yang; Hong Zhao; Xin Yu; Weihong Xu; Sandrine Roulland; Michele Ceribelli; Xiaohu Zhang; Kelli M. Wilson; Lu Chen; Crystal McKnight; Carleen Klumpp-Thomas; Craig J. Thomas; Björn Häupl; Thomas Oellerich; Zachary Rae; Michael C. Kelly; Inhye E. Ahn; Clare Sun; Erika M. Gaglione; Wyndham H. Wilson; Adrian Wiestner; Louis M. Staudt
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
Rebecca M. Richards; Feifei Zhao; Katherine A. Freitas; Kevin R. Parker; Peng Xu; Amy Fan; Elena Sotillo; Mads Daugaard; Htoo Zarni Oo; Jie Liu; Wan-Jen Hong; Poul H. Sorensen; Howard Y. Chang; Ansuman T. Satpathy; Robbie G. Majzner; Ravindra Majeti; Crystal L. Mackall
Advertisement